Summit Therapeutics (SMMT) is now covered by Citigroup Inc.. They set a "buy" rating on the stock.
Summit Therapeutics (SMMT) is now covered by Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.
A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing [Yahoo! Finance]
Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA Filing - What's Changed [Yahoo! Finance]
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026